Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial

Conclusions
In ADPKD, higher baseline albuminuria was associated with more eGFR loss. Tolvaptan decreased albuminuria compared with placebo, independent of blood pressure. Treatment efficacy of tolvaptan on changes in TKV and eGFR was more readily detected in patients with higher albuminuria.

Source: Nephrology Dialysis Transplantation - November 1, 2016 Category: Urology & Nephrology Authors: Gansevoort, R. T., Meijer, E., Chapman, A. B., Czerwiec, F. S., Devuyst, O., Grantham, J. J., Higashihara, E., Krasa, H. B., Ouyang, J., Perrone, R. D., Torres, V. E., for the TEMPO 3:4 Investigators Tags: Chronic Kidney Disease Source Type: research